Cable Hill Partners LLC lowered its holdings in Eli Lilly And Co (NYSE:LLY) by 16.5% during the 1st quarter, Holdings Channel reports. The firm owned 15,143 shares of the company’s stock after selling 3,000 shares during the quarter. Eli Lilly And Co makes up about 0.7% of Cable Hill Partners LLC’s portfolio, making the stock its 11th biggest holding. Cable Hill Partners LLC’s holdings in Eli Lilly And Co were worth $1,965,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Valmark Advisers Inc. grew its stake in shares of Eli Lilly And Co by 5.0% in the 1st quarter. Valmark Advisers Inc. now owns 2,175 shares of the company’s stock worth $282,000 after purchasing an additional 103 shares during the last quarter. Affinity Wealth Management LLC acquired a new position in shares of Eli Lilly And Co in the 1st quarter worth approximately $298,000. Tuttle Tactical Management grew its stake in shares of Eli Lilly And Co by 264.4% in the 1st quarter. Tuttle Tactical Management now owns 44,079 shares of the company’s stock worth $5,720,000 after purchasing an additional 31,983 shares during the last quarter. Balasa Dinverno & Foltz LLC grew its stake in shares of Eli Lilly And Co by 36.0% in the 1st quarter. Balasa Dinverno & Foltz LLC now owns 8,058 shares of the company’s stock worth $1,046,000 after purchasing an additional 2,133 shares during the last quarter. Finally, IPG Investment Advisors LLC grew its stake in shares of Eli Lilly And Co by 16.4% in the 1st quarter. IPG Investment Advisors LLC now owns 2,630 shares of the company’s stock worth $341,000 after purchasing an additional 370 shares during the last quarter. 79.42% of the stock is currently owned by institutional investors.
Shares of LLY opened at $111.82 on Friday. Eli Lilly And Co has a one year low of $84.64 and a one year high of $132.13. The stock has a market capitalization of $108.94 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 1.99 and a beta of 0.27. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of $1.32 by $0.01. The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted $1.31 earnings per share. As a group, analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Friday, May 17th were issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.31%. The ex-dividend date of this dividend was Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.
Several equities analysts have recently issued reports on the stock. Barclays reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Eli Lilly And Co in a research note on Sunday, April 14th. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a report on Wednesday, April 10th. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a report on Tuesday, April 30th. BMO Capital Markets raised their target price on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Finally, Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Thursday, March 21st. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $119.99.
In related news, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $128.50, for a total transaction of $128,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at $12,874,216. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 246,112 shares of company stock valued at $31,888,255. 0.11% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This article was first published by Riverton Roll and is owned by of Riverton Roll. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://rivertonroll.com/news/2019/06/14/cable-hill-partners-llc-sells-3000-shares-of-eli-lilly-and-co-nyselly.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What are the qualifications of a portfolio manager?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.